

Isecarosmab

Cat. No.:	HY-P99671
CAS No.:	2254082-79-4
Target:	ADAMTS
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a K_D value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life ^{[1][2][3]} .
In Vitro	Isecarosmab binds ADAMTS-5, but not ADAMTS-1, ADAMTS-4 and ADAMTS-15 ^[1] . Isecarosmab (1-100 nM, 5 days) decreases huARGS, exAGNxl and GAG after pro-inflammatory stimulation in the bovine and OA human cartilage explants ^[1] . Isecarosmab (24-72 h) blocks ADAMTS-5-mediated DCS TLR2 activation ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Isecarosmab (0.1-10 mg/kg mg/kg, s.c, every third day) decreases the medial cartilage degeneration in Medial meniscus (DMM) mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Siebuhr AS, et al. The Anti-ADAMTS-5 Nanobody® M6495 Protects Cartilage Degradation Ex Vivo. *Int J Mol Sci.* 2020 Aug 20;21(17):5992.
- [2]. Sharma N, et al. Inflammation and joint destruction may be linked to the generation of cartilage metabolites of ADAMTS-5 through activation of toll-like receptors. *Osteoarthritis Cartilage.* 2020 May;28(5):658-668.
- [3]. C. Brenneis. Structural and symptomatic benefit of a half-live extended, systemically applied anti-ADAMTS-5 inhibitor (M6495). 2018. 26 (1), S299-S300.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA